Table 1 Characteristics of included studies
References | Type | Number of Samples | NAC regimen | Median survival (months) | ||
|---|---|---|---|---|---|---|
NAC + RC | RC Only | NAC + RC | RC Only | |||
MVAC | ||||||
Kitamura et al. [11] | RCT | 64 | 66 | MVAC | 102 | 82 |
Grossman et al. [12] | RCT | 153 | 154 | MVAC | 77 | 46 |
GC | ||||||
Khaled et al. [13] | RCT | 59 | 59 | GC | NA | NA |
Osman et al. [14] | Clinical trial | 30 | 30 | GC | 36 | 28 |
Other regimens | ||||||
Lane et al. [15] | Retrospective cohort | 381 | 1505 | Cisplatin-based | NA | NA |
Anan et al. [16] | Retrospective cohort | 336 | 196 | GCarbo, GC, MVAC | NA | NA |
Hinata et al. [17] | Retrospective cohort | 69 | 69 | GC or MVAC | NA | NA |
Martinez-Pineiro et al. [18] | RCT | 62 | 60 | Cisplatin monotherapy | NA | NA |
Milenkovic et al. [19] | Retrospective cohort | 102 | 389 | NA | 106.7 | 60.1 |
Mozzane et al. [20] | Retrospective cohort | 1519 | 2459 | NA | NA | NA |
Gronostaj et al. [21] | Retrospective cohort | 79 | 76 | Cisplatin-based, GCarbo | NA | NA |
Boeri et al. [22] (2) | Retrospective cohort | 156 | 166 | Cisplatin-based (GC, MVAC), noncisplatin-based (combined PGC, or GCarbo) | NA | NA |
Nitta et al. [23] | Retrospective cohort | 69 | 71 | GC, MVAC, carboplatin, GN | NA | NA |
Ploussard et al. [24] | Retrospective cohort | 56 | 394 | MVAC, GC | 16.7 | 28.8 |
Russell et al. [25] | Retrospective cohort | 216 | 216 | No data available in BladderBase | NA | NA |
Vetterlein et al. [26] | Retrospective cohort | 369 | 1649 | NA | 51.7 | 29 |
Hermans et al. [27] (1) | Retrospective cohort | 191 | 4164 | NA (cT2 disease) | NA | NA |
Hermans et al. [27] (2) | Retrospective cohort | 133 | 834 | NA (cT3-4 disease) | NA | NA |